A new era for the design of TRPV1 antagonists and agonists with the use of structural information and molecular docking of capsaicin-like compounds

J Enzyme Inhib Med Chem. 2022 Dec;37(1):2169-2178. doi: 10.1080/14756366.2022.2110089.

Abstract

The design of TRPV1 antagonists and agonists has reached a new era since TRPV1 structures at near-atomic resolution are available. Today, the ligand-binding forms of several classical antagonists and agonists are known; therefore, the specific role of key TRPV1's residues in binding of ligands can be elucidated. It is possible to place the well-defined pharmacophore of TRPV1 ligands, conformed by head, neck, and tail groups, in the right pocket regions of TRPV1. It will allow a more thorough use of molecular modelling methods to conduct more effective rational drug design protocols. In this work, important points about the interactions between TRPV1 and capsaicin-like compounds are spelled out, based on the known pharmacophore of the ligands and the already available TRPV1 structures. These points must be addressed to generate reliable poses of novel candidates and should be considered during the design of novel TRPV1 antagonists and agonists.

Keywords: TRPV1 agonists; TRPV1 antagonists; capsaicin receptor; molecular docking.

MeSH terms

  • Capsaicin* / chemistry
  • Capsaicin* / metabolism
  • Capsaicin* / pharmacology
  • Ligands
  • Models, Molecular
  • Molecular Docking Simulation
  • TRPV Cation Channels* / chemistry
  • TRPV Cation Channels* / metabolism

Substances

  • Ligands
  • TRPV Cation Channels
  • Capsaicin

Grants and funding

This research was funded by FONDECYT Regular grant number 1210138